Overview

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This will be a phase 1 randomized, double-blind crossover trial enrolling approximately 12 healthy volunteers to assess whether intravenous (IV) UFH and IV Bendavia administered together have any significant impact on the pharmacodynamic effects of UFH and the pharmacokinetics of Bendavia.
Phase:
Phase 1
Details
Lead Sponsor:
Stealth BioTherapeutics Inc.
Treatments:
Calcium heparin
Heparin